Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

September 11, 2020September 11, 2020

Procalcitonin Blood Levels May Help Detect Lung Cancer in IPF Patients, Study Suggests

News

Procalcitonin, a precursor of the calcitonin hormone, may be used as a potential biomarker of lung cancer developing in people with idiopathic pulmonary fibrosis (IPF), a recent study suggests. ... Read more

September 4, 2020September 4, 2020

NIH Grants $10M to Study Immune Cells’ Role in Lung, Heart Transplant Rejection

News

Research investigating the role of immune cells in triggering lung and heart rejection following transplant will be supported by $10 million in grants from the National Institutes of Health ... Read more

August 19, 2020August 20, 2020

Gene Therapy Halts Age-related Lung Fibrosis, Mouse Study Shows

News

A gene therapy that lengthens the life of lung cells can halt scarring and help sustain lung regeneration in a mouse model of age-related pulmonary fibrosis, a new study ... Read more

August 12, 2020August 12, 2020

Real-world Data Support Envisia Classifier in More Easily Diagnosing IPF

News

Veracyte’s Envisia Genomic Classifier can aid in the diagnosis of idiopathic pulmonary fibrosis (IPF) and distinguish it from other interstitial lung diseases (ILDs) without the need for invasive, expensive, and risky ... Read more

August 10, 2020August 11, 2020

Potential Cancer Treatment, Barasertib, Might Lessen Lung Fibrosis in IPF

News

Note: This story was updated Aug. 11, 2020, to correct the name of the factor involved in fibrosis to TGF-alpha rather than TNF-alpha. Barasertib, AstraZeneca’s investigational inhibitor of the ... Read more

July 28, 2020July 28, 2020

Tailored Exercise May Aid With Lung Transplants in IPF Patients

News

A three-year pulmonary rehabilitation program — a combination of aerobic, resistance, and breathing exercises — helped to maintain lung and muscle strength before a double-lung transplant in a middle-aged ... Read more

July 24, 2020July 24, 2020

Tobacco, Dust, and Asbestos Exposure at Work Raises Risk for IPF, Australian Study Finds

News

Exposure to secondhand smoke, dust, or asbestos in the workplace is linked to a significantly higher risk of developing idiopathic pulmonary fibrosis (IPF), according to findings of an Australian ... Read more

July 20, 2020July 23, 2020

Distinct Groups of Epithelial Cells Identified That May Drive PF Progression

News

Researchers have discovered the existence of unique subtypes of epithelial cells in the lungs of people with pulmonary fibrosis (PF) that may drive tissue scarring, or fibrosis. Their findings ... Read more

June 3, 2020June 3, 2020

Mortality Risk 37% Lower in IPF Patients on Ofev or Esbriet, Study Reports

Esbriet, News

Idiopathic pulmonary fibrosis (IPF) patients taking antifibrotic therapies Ofev (nintedanib) or Esbriet (pirfenidone) had a mortality risk that was 37% lower than patients not treated with such therapies, a large registry-based study ... Read more

May 27, 2020May 27, 2020

Real-world Study Supports Effectiveness, Safety of Esbriet for Treating IPF

Esbriet, News

A real-world, multi-center study in Poland confirms the effectiveness and safety of two-year treatment with Esbriet (pirfenidone) for people with idiopathic pulmonary fibrosis (IPF). The study “A multicentre retrospective observational study on ... Read more